Loading...
XNASADXN
Market cap214mUSD
Dec 23, Last price  
7.63USD
1D
-3.42%
1Q
-25.27%
IPO
-47.38%
Name

Addex Therapeutics Ltd

Chart & Performance

D1W1MN
XNAS:ADXN chart
P/E
—
P/S
718.53
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
26.11%
Rev. gr., 5y
-23.22%
Revenues
2m
+13.39%
4,738,970486,93026,806,8424,090,7701,975,2652,823,447121,08991,76085,40440,30117,329499,8946,043,8552,762,8303,612,8192,916,3081,422,4381,612,953
Net income
-11m
L-49.26%
-20,544,810-35,085,760-22,066,277-42,692,124-33,645,347-31,141,068-26,611,480-14,461,828-1,774,858-4,204,213-3,149,386-3,280,406-1,644,798-14,780,604-12,858,599-15,351,914-20,804,213-10,556,227
CFO
-8m
L-51.38%
-19,559,410-33,004,880-17,791,659-39,376,384-31,340,904-26,550,631-29,452,938-15,776,368-1,799,642-2,628,443-2,694,387-2,134,9521,751,729-9,482,104-12,180,067-14,705,185-16,437,185-7,992,411

Profile

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
URL
https://www.addextherapeutics.com/
IPO date
May 22, 2007
Employees
24
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,613
13.39%
1,422
-51.22%
2,916
-19.28%
Cost of revenue
16,889
36,589
30,797
Unusual Expense (Income)
NOPBT
(15,276)
(35,166)
(27,881)
NOPBT Margin
Operating Taxes
124
116
Tax Rate
NOPAT
(15,276)
(35,290)
(27,997)
Net income
(10,556)
-49.26%
(20,804)
35.52%
(15,352)
19.39%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,351
3,103
16,380
BB yield
-68.77%
-65.39%
-45.79%
Debt
Debt current
274
286
288
Long-term debt
415
460
676
Deferred revenue
Other long-term liabilities
533
1,282
Net debt
(3,178)
(6,214)
(19,538)
Cash flow
Cash from operating activities
(7,992)
(16,437)
(14,705)
CAPEX
(7)
(581)
(32)
Cash from investing activities
(7)
3
(30)
Cash from financing activities
5,265
3,103
16,403
FCF
(15,230)
(35,147)
(27,906)
Balance
Cash
3,866
6,960
20,502
Long term investments
Excess cash
3,786
6,889
20,356
Stockholders' equity
(328,760)
(322,940)
(255,347)
Invested Capital
330,782
328,105
273,838
ROIC
ROCE
EV
Common stock shares outstanding
74,308
45,185
34,120
Price
0.05
-56.20%
0.11
-89.98%
1.05
-53.06%
Market cap
3,418
-27.97%
4,745
-86.73%
35,769
-39.97%
EV
240
(1,469)
16,231
EBITDA
(14,970)
(34,843)
(27,533)
EV/EBITDA
0.04
Interest
22
49
63
Interest/NOPBT